Michael Buchert

List of Publications by Year
in descending order

44 papers	3,011 citations	218677 26 h-index	254184 43 g-index
49 all docs	49 docs citations	49 times ranked	4914 citing authors

#	Article	IF	Citations
1	Transcription factor AP-2 essential for cranial closure and craniofacial development. Nature, 1996, 381, 235-238.	27.8	581
2	STAT3 and STAT1 mediate IL-11â€“dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. Journal of Clinical Investigation, 2008, 118, 1727-38.	8.2	276
3	The Junction-associated Protein AF-6 Interacts and Clusters with Specific Eph Receptor Tyrosine Kinases at Specialized Sites of Cellâ€“Cell Contact in the Brain. Journal of Cell Biology, 1999, 144, 361-371.	5.2	187
4	Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene, 2016, 35, 939-951.	5.9	173
5	Ryk-deficient mice exhibit craniofacial defects associated with perturbed Eph receptor crosstalk. Nature Genetics, 2000, 25, 414-418.	21.4	157
6	The JAK/STAT3 axis: A comprehensive drug target for solid malignancies. Seminars in Cancer Biology, 2017, 45, 13-22.	9.6	147
7	IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization. Nature Communications, 2019, 10, 2735.	12.8	139
8	Defective Claudin-7 Regulation by Tcf-4 and Sox-9 Disrupts the Polarity and Increases the Tumorigenicity of Colorectal Cancer Cells. Cancer Research, 2008, 68, 4258-4268.	0.9	108
9	mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. Journal of Clinical Investigation, 2013, 123, 767-81.	8.2	89
10	Mutagenesis and selection of PDZ domains that bind new protein targets. Nature Biotechnology, 1999, 17, 170-175.	17.5	84
11	An In Vitro Assay of Î²-Galactosidase from Yeast. BioTechniques, 1996, 20, 960-962.	1.8	81
12	Genetic Dissection of Differential Signaling Threshold Requirements for the Wnt/Î²-Catenin Pathway In Vivo. PLoS Genetics, 2010, 6, e1000816.	3.5	81
13	DNA-methylation-dependent alterations of claudin-4 expression in human bladder carcinoma. Carcinogenesis, 2007, 28, 246-258.	2.8	79
14	Symplekin promotes tumorigenicity by up-regulating claudin-2 expression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2628-2633.	7.1	69
15	Functional interaction between the ZO-1-interacting transcription factor ZONAB/DbpA and the RNA processing factor symplekin. Journal of Cell Science, 2006, 119, 5098-5105.	2.0	68
16	Partial inhibition of gp130-Jak-Stat3 signaling prevents Wntâ€“Î²-cateninâ€“mediated intestinal tumor growth and regeneration. Science Signaling, 2014, 7, ra92.	3.6	68
17	Biochemical and Structural Insights into Doublecortin-like Kinase Domain 1. Structure, 2016, 24, 1550-1561.	3.3	56
18	MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors. Cancer Discovery, 2018, 8, 988-1005.	9.4	55

#	Article	IF	Citations
19	Distinct requirements for the Sprouty domain for functional activity of Spred proteins. Biochemical Journal, 2005, 388, 445-454.	3.7	41
20	Î²-Catenin/Tcf-4 Inhibition After Progastrin Targeting Reduces Growth and Drives Differentiation of Intestinal Tumors. Gastroenterology, 2007, 133, 1554-1568.	1.3	41
21	Methods to Examine Tight Junction Physiology in Cancer Stem Cells: TEER, Paracellular Permeability, and Dilution Potential Measurements. Stem Cell Reviews and Reports, 2012, 8, 1030-1034.	5.6	35
22	Elevated Dnmt3a Activity Promotes Polyposis in ApcMin Mice by Relaxing Extracellular Restraints on Wnt Signaling. Gastroenterology, 2009, 137, 902-913.e11.	1.3	34
23	The Symplekin/ZONAB Complex Inhibits Intestinal Cell Differentiation by the Repression of AML1/Runx1. Gastroenterology, 2009, 137, 156-164.e3.	1.3	33
24	Stomach-Specific Activation of Oncogenic KRAS and STAT3-Dependent Inflammation Cooperatively Promote Gastric Tumorigenesis in a Preclinical Model. Cancer Research, 2016, 76, 2277-2287.	0.9	33
25	Repurposing the selective estrogen receptor modulator bazedoxifene to suppress gastrointestinal cancer growth. EMBO Molecular Medicine, 2019, 11, .	6.9	32
26	Therapeutic Inhibition of Jak Activity Inhibits Progression of Gastrointestinal Tumors in Mice. Molecular Cancer Therapeutics, 2014, 13, 468-474.	4.1	31
27	Glycoprotein A33 deficiency: a new model of impaired intestinal epithelial barrier function and inflammatory disease. DMM Disease Models and Mechanisms, 2015, 8, 805-15.	2.4	28
28	AF6/sâ€afadin is a dual residency protein and localizes to a novel subnuclear compartment. Journal of Cellular Physiology, 2007, 210, 212-223.	4.1	27
29	IL33 and Mast Cellsâ€"The Key Regulators of Immune Responses in Gastrointestinal Cancers?. Frontiers in Immunology, 2020, 11, 1389.	4.8	23
30	Machine learning for medical imagingâ€based COVIDâ€19 detection and diagnosis. International Journal of Intelligent Systems, 2021, 36, 5085-5115.	5.7	22
31	Useful Vectors for the Two-Hybrid System in Mammalian Cells. BioTechniques, 1997, 23, 396-402.	1.8	21
32	Eve-3: A liver enriched suppressor of Ras/MAPK signaling. Journal of Hepatology, 2006, 44, 758-767.	3.7	16
33	Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells. Proteomics, 2021, 21, e2000098.	2.2	15
34	A hypermorphic epithelial beta-catenin mutation facilitates intestinal tumorigenesis in mice in response to compounding WNT-pathway mutations. DMM Disease Models and Mechanisms, 2015, 8, 1361-73.	2.4	11
35	Onco-miR-21 Promotes Stat3-Dependent Gastric Cancer Progression. Cancers, 2022, 14, 264.	3.7	11
36	Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK. Molecular Cancer Therapeutics, 2021, 20, 704-715.	4.1	10

#	Article	IF	Citations
37	An epitope tagged mammalian/prokaryotic expression vector with positive selection of cloned inserts. Gene, 1997, 197, 337-341.	2.2	9
38	Generation of an inducible mouse model to reversibly silence Stat3. Genesis, 2017, 55, e23023.	1.6	9
39	EHF is essential for epidermal and colonic epithelial homeostasis, and suppresses Apc-initiated colonic tumorigenesis. Development (Cambridge), 2021, 148, .	2.5	8
40	Inducible gene modification in the gastric epithelium of Tff1â€CreERT2, Tff2â€rtTA, Tff3â€luc mice. Genesis, 2016, 54, 626-635.	1.6	6
41	Combined Treatment with a WNT Inhibitor and the NSAID Sulindac Reduces Colon Adenoma Burden in Mice with Truncated APC. Cancer Research Communications, 2022, 2, 66-77.	1.7	5
42	Linking inflammation to cancer â€“ A novel role for Stat3. Cytokine, 2009, 48, 44.	3.2	3
43	150. Cytokine, 2014, 70, 64.	3.2	0
44	Abstract LB-262: Excessive Wnt activity is insufficient for intestinal tumor growth or regeneration without gp130/Jak2/Stat3 signaling.. , 2013, , .		0